Mr. Hermouet joined Athyrium in 2009 and currently serves as a Partner. Mr. Hermouet has more than ten years experience in credit analysis, investing in corporate credit instruments across both liquid and structured markets.
From 2004 to 2008, Mr. Hermouet was a Vice-President and Senior Credit Analyst at Tribeca Global Management, the two billion dollars multi-strategy hedge fund platform of Citigroup Alternative Investments, focusing on convertible and high-yield bonds including healthcare and biotech related issues. In addition to investing in corporate bonds, Mr. Hermouet worked on other credit-driven investments such as leveraged loans and distressed securities. Representative investments include CV Therapeutics (acquired by Gilead Sciences), Connectics (acquired by Stiefel Laboratories), Nektar Therapeutics, Human Genome Sciences and Amgen.
Prior thereto, Mr. Hermouet served in a number of capacities at Goldman Sachs from 1998 to 2004, including four years in the Goldman Sachs’ credit department as a credit analyst. In that capacity, Mr. Hermouet worked closely with Companies’ treasurers, CFOs and their investment bankers to structure credit driven capital raises and analyze the impact of these transactions on the issuer’s credit profile. Mr. Hermouet monitored the resulting multi-million dollar credit exposure portfolios on Goldman Sachs’ balance sheet.
Mr. Hermouet graduated with a BS in Economics and a Masters in Banking & Finance from the University of Paris-Dauphine. He has been a CFA charterholder and a member of the New York Society of Security Analysts since 2001.